EricS.DaarMD

Infectious Disease • Torrance, CA

Professor of Medicine, UCLA-David Geffen School of Medicine

Join to view full profile

Dr. Daar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Daar's full profile

Already have an account?

Office
21840 Normandie Ave
Ste 700
Torrance, CA 90502
Phone+1 310-222-5101

Fax+1 310-320-5463

Education & Training

Cedars-Sinai Medical CenterFellowship, Infectious Disease, 1988 - 1991
Cedars-Sinai Medical CenterResidency, Internal Medicine, 1985 - 1988
Georgetown University School of MedicineClass of 1985

Certifications & Licensure

CA State Medical License 1986 - 2025
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2003-2014
Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

The Biology of HIV Transmission Start of enrollment: 1999 Oct 01
Completed
Outcomes of Anti-HIV Therapy During Early HIV Infection Start of enrollment: 1999 Oct 01
Completed
Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination
Terminated
Phase 1
Treatment of Depression With Massage in HIV Start of enrollment: 2002 Apr 01
Completed
Phase 2
Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults Start of enrollment: 2005 Sep 01
Completed
Phase 3
A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules Start of enrollment: 2006 Feb 14
Completed
Phase 4
CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM Start of enrollment: 2012 Dec 19
Completed
Phase 4
CCTG 594: Engagement and Retention in Care for HIV+ Start of enrollment: 2013 Oct 08
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

107 citations
Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV Controllers
Toshiyuki Miura, Zabrina L. Brumme, Mark A. Brockman, Pamela C. Rosato, Jennifer Sela
Journal of Virology. 2010-08-01
259 citations
Modeling plasma virus concentration during primary HIV infection.
Max A. Stafford, Lawrence Corey, Yunzhen Cao, Eric S. Daar, David D. Ho
Journal of Theoretical Biology. 2000-04-07
190 citations
Clinical targeting of HIV capsid protein with a long-acting small molecule.
John O. Link, Martin S. Rhee, Tse Winston C, Jim Zheng, John R. Somoza
Nature. 2020-07-01

Journal Articles

Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1
Jill S Blumenthal, Eric S Daar, Centers for Disease Control and Prevention
Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1
Jill S Blumenthal, Eric S Daar, Centers for Disease Control and Prevention
Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Grou...
Steven G Deeks, James H Stein, Carl Fichtenbaum, Judith S Currier, Priscilla Y Hsue, Eric S Daar, Ahmed Tawakol, Michael Lederman, Tanvir Bell, Diane Havlir, Clinical Infectious Diseases
Switching to Coformulated Rilpivirine (RPV), Emtricitabine (FTC) and Tenofovir Alafenamide from Either RPV, FTC and Tenofovir Disoproxil Fumarate (TDF) or Efavirenz, F...
E S Daar, O Osiyemi, D Porter, M Thompson, C Martorell, HIV Medicine
Join now to see all

Other

Evaluation of the treatment-experienced patient with drug-resistant HIV infection
Daar ES, Lagnese M
http://www.uptodate.com/contents/evaluation-of-the-treatment-experienced-patient-with-drug-resistant
UpToDate, Wolters Kluwer Health - 2012-12-21
Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection
Daar ES, Lagnese M
http://www.uptodate.com/contents/selection-of-antiretroviral-therapy-for-the-treatment-experienced-p
UpToDate, Wolters Kluwer Health - 2013-01-24

Authored Content

Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1November 2018

Press Mentions

Risks of Removing Ovaries at Benign Hysterectomy May Outweigh the Benefits for Women at Low Risk for Ovarian CancerApril 17th, 2023
At IDWeek, New Insights into Long COVIDOctober 21st, 2022
ACTIV-2d, a Global Phase 3 Trial of Novel Investigational COVID-19 Oral Antiviral Agent, LaunchesAugust 22nd, 2022
Join now to see all

Grant Support

Clinical Trial: A Phase IIIB, Randomized, Trial Of Open-Label Efavirenz Or AtazaNational Center For Research Resources2010
Clinical Trial: A Phase III Comparative Study Of Three Non-Nucleoside Reverse TRNational Center For Research Resources2010
California Neuroaids Tissue Network (CNTN)National Center For Research Resources2010
A Longitudinal Study Of Cerebral And Neurocognitive FunctionNational Center For Research Resources2009–2010
Long-Term Metabolic Assessments In Subjects Treated With Emtricitabine/TenofoNational Center For Research Resources2007–2010
California Neuro AIDS Tissue NetworkNational Center For Research Resources2004–2010
A Phase II/III Randomized, Double-Blind, Placebo-Controlled TriaNational Center For Research Resources2009
Clinical Trial: A Phase II/III Randomized, Double-Blind, Placebo-Controlled TriaNational Center For Research Resources2008
Acute HIV Infection And Early Disease Research Program (AIEDRP)National Center For Research Resources2005–2008
California Neuro - AIDS Tissue NetworkNational Center For Research Resources2004–2008
Pathogenesis Of Primary HIV InfectionNational Center For Research Resources1998–2008
The Setpoint Study - A Randomized Study Of The Effect Of Immediate TreatmentNational Center For Research Resources2007
A Phase III, Randomized, Open-Label, Comparison Of Lopinavir/Ritonavir PLUS ENational Center For Research Resources2005–2007
Phase III, Randomized, Open-Label, Comparison Of LopinNational Center For Research Resources2004